Skip to content
RDL Network logo
804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial — Alexander M.M. Eggermont (2022) | RDL Network